Evelyn Wang1, Lukas Kraehenbuehl2, Kwami Ketosugbo3, Jeffrey A Kern4, Mario E Lacouture5, Donald Y M Leung6. 1. Department of Pediatrics, National Jewish Health, Denver, Colorado. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Swim Across America/Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Cancer Center, Division of Oncology, Department of Medicine, National Jewish Health, Denver, Colorado. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Weill Cornell Medical College, New York, New York. 6. Department of Pediatrics, National Jewish Health, Denver, Colorado. Electronic address: leungd@njhealth.org.
Abstract
OBJECTIVE: To familiarize the reader with the most common cutaneous adverse events with immune checkpoint inhibitors (CPIs) and their grading and treatment. DATA SOURCES: Recent research articles, relevant review articles, and case series/reports in English from the PubMed database mostly, from 2010 onward. STUDY SELECTIONS: Most data are from retrospective studies and case series. Older studies regarding the mechanism were included if they were of particular importance. RESULTS: An understanding of this review should enable the reader to identify specific skin disorders in patients receiving immune CPIs, grade the adverse event, and be able to treat or refer the patient as needed. CONCLUSION: Allergists/immunologists need to be familiar with these immune-related cutaneous adverse events because their incidence will increase with the ever-expanding use of CPIs and, in particular, because patients will certainly continue to be referred suspecting drug allergies.
OBJECTIVE: To familiarize the reader with the most common cutaneous adverse events with immune checkpoint inhibitors (CPIs) and their grading and treatment. DATA SOURCES: Recent research articles, relevant review articles, and case series/reports in English from the PubMed database mostly, from 2010 onward. STUDY SELECTIONS: Most data are from retrospective studies and case series. Older studies regarding the mechanism were included if they were of particular importance. RESULTS: An understanding of this review should enable the reader to identify specific skin disorders in patients receiving immune CPIs, grade the adverse event, and be able to treat or refer the patient as needed. CONCLUSION: Allergists/immunologists need to be familiar with these immune-related cutaneous adverse events because their incidence will increase with the ever-expanding use of CPIs and, in particular, because patients will certainly continue to be referred suspecting drug allergies.
Authors: Lidia Robert; Jennifer Tsoi; Xiaoyan Wang; Ryan Emerson; Blanca Homet; Thinle Chodon; Stephen Mok; Rong Rong Huang; Alistair J Cochran; Begoña Comin-Anduix; Richard C Koya; Thomas G Graeber; Harlan Robins; Antoni Ribas Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531
Authors: Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru Journal: J Am Acad Dermatol Date: 2020-04-29 Impact factor: 11.527
Authors: Gregory S Phillips; Jennifer Wu; Matthew D Hellmann; Michael A Postow; Naiyer A Rizvi; Azael Freites-Martinez; Donald Chan; Stephen Dusza; Robert J Motzer; Jonathan E Rosenberg; Margaret K Callahan; Paul B Chapman; Larisa Geskin; Adriana T Lopez; Vanessa A Reed; Gabriella Fabbrocini; Maria Carmela Annunziata; Oluwaseun Kukoyi; Aliyah Pabani; Chih-Hsun Yang; Wen-Hung Chung; Alina Markova; Mario E Lacouture Journal: J Clin Oncol Date: 2019-06-19 Impact factor: 50.717
Authors: Hywel C Williams; Fenella Wojnarowska; Gudula Kirtschig; James Mason; Thomas R Godec; Enno Schmidt; Joanne R Chalmers; Margaret Childs; Shernaz Walton; Karen Harman; Anna Chapman; Diane Whitham; Andrew J Nunn Journal: Lancet Date: 2017-03-06 Impact factor: 79.321
Authors: Alyce M Kuo; Lukas Kraehenbuehl; Stephanie King; Donald Y M Leung; Elena Goleva; Andrea P Moy; Mario E Lacouture; Neil J Shah; David M Faleck Journal: Cancers (Basel) Date: 2022-06-17 Impact factor: 6.575
Authors: Elena Goleva; Taras Lyubchenko; Lukas Kraehenbuehl; Mario E Lacouture; Donald Y M Leung; Jeffrey A Kern Journal: Ann Allergy Asthma Immunol Date: 2021-03-11 Impact factor: 6.248